FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1993927422> ?p ?o ?g. }

• W1993927422 endingPage "74" @default.
• W1993927422 startingPage "67" @default.
• W1993927422 abstract "Purpose To investigate the differences in outcomes among patients with muscle-invasive bladder cancer on NRG Oncology Radiation Therapy Oncology Group protocols 9906 and 0233 who achieved complete response and near-complete response after induction chemoradiation and then completed bladder-preserving therapy with chemoradiation therapy (chemo-RT) to full dose (60-64 Gy). Patients and Methods A pooled analysis was performed on 119 eligible patients with muscle-invasive bladder cancer enrolled on NRG Oncology Radiation Therapy Oncology Group trials 9906 and 0233, who were classified as having a complete (T0) or near-complete (Ta or Tis) response after induction chemo-RT and completed consolidation with a total RT dose of at least 60 Gy. Bladder recurrence, salvage cystectomy rates, and disease-specific survival were estimated by the cumulative incidence method and bladder-intact and overall survivals by the Kaplan-Meier method. Results Among the 119 eligible patients, 101 (85%) achieved T0, and 18 (15%) achieved Ta or Tis after induction chemo-RT and proceeded to consolidation. After a median follow-up of 5.9 years, 36 of 101 T0 patients (36%) versus 5 of 18 Ta or Tis patients (28%) experienced bladder recurrence (P=.52). Thirteen patients among complete responders eventually required late salvage cystectomy for tumor recurrence, compared with 1 patient among near-complete responders (P=.63). Disease-specific, bladder-intact, and overall survivals were not significantly different between T0 and Ta/Tis cases. Conclusions The bladder recurrence and salvage cystectomy rates of the complete and the near-complete responders were similar. Therefore it is reasonable to recommend that patients with Ta or Tis after induction chemo-RT continue with bladder-sparing therapy with consolidation chemo-RT to full dose (60-64 Gy). To investigate the differences in outcomes among patients with muscle-invasive bladder cancer on NRG Oncology Radiation Therapy Oncology Group protocols 9906 and 0233 who achieved complete response and near-complete response after induction chemoradiation and then completed bladder-preserving therapy with chemoradiation therapy (chemo-RT) to full dose (60-64 Gy). A pooled analysis was performed on 119 eligible patients with muscle-invasive bladder cancer enrolled on NRG Oncology Radiation Therapy Oncology Group trials 9906 and 0233, who were classified as having a complete (T0) or near-complete (Ta or Tis) response after induction chemo-RT and completed consolidation with a total RT dose of at least 60 Gy. Bladder recurrence, salvage cystectomy rates, and disease-specific survival were estimated by the cumulative incidence method and bladder-intact and overall survivals by the Kaplan-Meier method. Among the 119 eligible patients, 101 (85%) achieved T0, and 18 (15%) achieved Ta or Tis after induction chemo-RT and proceeded to consolidation. After a median follow-up of 5.9 years, 36 of 101 T0 patients (36%) versus 5 of 18 Ta or Tis patients (28%) experienced bladder recurrence (P=.52). Thirteen patients among complete responders eventually required late salvage cystectomy for tumor recurrence, compared with 1 patient among near-complete responders (P=.63). Disease-specific, bladder-intact, and overall survivals were not significantly different between T0 and Ta/Tis cases. The bladder recurrence and salvage cystectomy rates of the complete and the near-complete responders were similar. Therefore it is reasonable to recommend that patients with Ta or Tis after induction chemo-RT continue with bladder-sparing therapy with consolidation chemo-RT to full dose (60-64 Gy)." @default.
• W1993927422 created "2016-06-24" @default.
• W1993927422 creator A5001714656 @default.
• W1993927422 creator A5012866369 @default.
• W1993927422 creator A5023563011 @default.
• W1993927422 creator A5024741202 @default.
• W1993927422 creator A5043554307 @default.
• W1993927422 creator A5044977805 @default.
• W1993927422 creator A5045162411 @default.
• W1993927422 creator A5062118116 @default.
• W1993927422 creator A5064493505 @default.
• W1993927422 creator A5068642720 @default.
• W1993927422 creator A5082076153 @default.
• W1993927422 creator A5087681485 @default.
• W1993927422 date "2016-01-01" @default.
• W1993927422 modified "2023-10-17" @default.
• W1993927422 title "Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233" @default.
• W1993927422 cites W1774531900 @default.
• W1993927422 cites W1786366031 @default.
• W1993927422 cites W1932620090 @default.
• W1993927422 cites W1975918912 @default.
• W1993927422 cites W1985950314 @default.
• W1993927422 cites W1997613830 @default.
• W1993927422 cites W2031304217 @default.
• W1993927422 cites W2057853521 @default.
• W1993927422 cites W2065741451 @default.
• W1993927422 cites W2071306483 @default.
• W1993927422 cites W2072167013 @default.
• W1993927422 cites W2073140442 @default.
• W1993927422 cites W2118328604 @default.
• W1993927422 cites W2130962341 @default.
• W1993927422 cites W2135108459 @default.
• W1993927422 cites W2139817908 @default.
• W1993927422 cites W2139984188 @default.
• W1993927422 cites W2167807146 @default.
• W1993927422 cites W2290195878 @default.
• W1993927422 cites W2313608588 @default.
• W1993927422 cites W4293241248 @default.
• W1993927422 doi "https://doi.org/10.1016/j.ijrobp.2015.09.030" @default.
• W1993927422 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4690848" @default.
• W1993927422 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26700703" @default.
• W1993927422 hasPublicationYear "2016" @default.
• W1993927422 type Work @default.
• W1993927422 sameAs 1993927422 @default.
• W1993927422 citedByCount "36" @default.
• W1993927422 countsByYear W19939274222015 @default.
• W1993927422 countsByYear W19939274222016 @default.
• W1993927422 countsByYear W19939274222017 @default.
• W1993927422 countsByYear W19939274222018 @default.
• W1993927422 countsByYear W19939274222019 @default.
• W1993927422 countsByYear W19939274222020 @default.
• W1993927422 countsByYear W19939274222021 @default.
• W1993927422 countsByYear W19939274222022 @default.
• W1993927422 countsByYear W19939274222023 @default.
• W1993927422 crossrefType "journal-article" @default.
• W1993927422 hasAuthorship W1993927422A5001714656 @default.
• W1993927422 hasAuthorship W1993927422A5012866369 @default.
• W1993927422 hasAuthorship W1993927422A5023563011 @default.
• W1993927422 hasAuthorship W1993927422A5024741202 @default.
• W1993927422 hasAuthorship W1993927422A5043554307 @default.
• W1993927422 hasAuthorship W1993927422A5044977805 @default.
• W1993927422 hasAuthorship W1993927422A5045162411 @default.
• W1993927422 hasAuthorship W1993927422A5062118116 @default.
• W1993927422 hasAuthorship W1993927422A5064493505 @default.
• W1993927422 hasAuthorship W1993927422A5068642720 @default.
• W1993927422 hasAuthorship W1993927422A5082076153 @default.
• W1993927422 hasAuthorship W1993927422A5087681485 @default.
• W1993927422 hasBestOaLocation W19939274222 @default.
• W1993927422 hasConcept C121608353 @default.
• W1993927422 hasConcept C126322002 @default.
• W1993927422 hasConcept C126894567 @default.
• W1993927422 hasConcept C141071460 @default.
• W1993927422 hasConcept C143998085 @default.
• W1993927422 hasConcept C2775910329 @default.
• W1993927422 hasConcept C2780352672 @default.
• W1993927422 hasConcept C509974204 @default.
• W1993927422 hasConcept C71924100 @default.
• W1993927422 hasConcept C72563966 @default.
• W1993927422 hasConcept C88879693 @default.
• W1993927422 hasConceptScore W1993927422C121608353 @default.
• W1993927422 hasConceptScore W1993927422C126322002 @default.
• W1993927422 hasConceptScore W1993927422C126894567 @default.
• W1993927422 hasConceptScore W1993927422C141071460 @default.
• W1993927422 hasConceptScore W1993927422C143998085 @default.
• W1993927422 hasConceptScore W1993927422C2775910329 @default.
• W1993927422 hasConceptScore W1993927422C2780352672 @default.
• W1993927422 hasConceptScore W1993927422C509974204 @default.
• W1993927422 hasConceptScore W1993927422C71924100 @default.
• W1993927422 hasConceptScore W1993927422C72563966 @default.
• W1993927422 hasConceptScore W1993927422C88879693 @default.
• W1993927422 hasIssue "1" @default.
• W1993927422 hasLocation W19939274221 @default.
• W1993927422 hasLocation W19939274222 @default.
• W1993927422 hasLocation W19939274223 @default.
• W1993927422 hasLocation W19939274224 @default.
• W1993927422 hasOpenAccess W1993927422 @default.
• W1993927422 hasPrimaryLocation W19939274221 @default.
• W1993927422 hasRelatedWork W2109785281 @default.

• next